Literature DB >> 21846562

Aggregation, stability, and formulation of human antibody therapeutics.

D Lowe1, K Dudgeon, R Rouet, P Schofield, L Jermutus, D Christ.   

Abstract

Many human monoclonal antibodies display poor biophysical properties, such as low stability and a propensity to aggregate. These unfavorable tendencies can be even more pronounced for human antibody fragments, which often require a considerable degree of optimization. In this review, we describe methods for analyzing aggregation and stability of human antibodies and antibody fragments. We also provide an overview of recent approaches to improve these properties through engineering and formulation.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21846562     DOI: 10.1016/B978-0-12-386483-3.00004-5

Source DB:  PubMed          Journal:  Adv Protein Chem Struct Biol        ISSN: 1876-1623            Impact factor:   3.507


  51 in total

1.  Expression of high-affinity human antibody fragments in bacteria.

Authors:  Romain Rouet; David Lowe; Kip Dudgeon; Brendan Roome; Peter Schofield; David Langley; John Andrews; Peter Whitfeld; Lutz Jermutus; Daniel Christ
Journal:  Nat Protoc       Date:  2012-02-02       Impact factor: 13.491

2.  General strategy for the generation of human antibody variable domains with increased aggregation resistance.

Authors:  Kip Dudgeon; Romain Rouet; Iris Kokmeijer; Peter Schofield; Jessica Stolp; David Langley; Daniela Stock; Daniel Christ
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-27       Impact factor: 11.205

3.  Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach.

Authors:  Andreas Lehmann; Josephine H F Wixted; Maxim V Shapovalov; Heinrich Roder; Roland L Dunbrack; Matthew K Robinson
Journal:  MAbs       Date:  2015-09-04       Impact factor: 5.857

4.  Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates.

Authors:  Kalli C Catcott; Molly A McShea; Carl Uli Bialucha; Kathy L Miller; Stuart W Hicks; Parmita Saxena; Thomas G Gesner; Mikias Woldegiorgis; Megan E Lewis; Chen Bai; Michael S Fleming; Seth A Ettenberg; Hans K Erickson; Nicholas C Yoder
Journal:  MAbs       Date:  2016-01-11       Impact factor: 5.857

Review 5.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

Review 6.  High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.

Authors:  Rajoshi Chaudhuri; Yuan Cheng; C Russell Middaugh; David B Volkin
Journal:  AAPS J       Date:  2013-10-31       Impact factor: 4.009

7.  Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration.

Authors:  Sorina Morar-Mitrica; Manasi Puri; Alexandra Beumer Sassi; Joshua Fuller; Ping Hu; George Crotts; Douglas Nesta
Journal:  MAbs       Date:  2015       Impact factor: 5.857

8.  A novel screening method to assess developability of antibody-like molecules.

Authors:  Neeraj Kohli; Nidhi Jain; Melissa L Geddie; Maja Razlog; Lihui Xu; Alexey A Lugovskoy
Journal:  MAbs       Date:  2015       Impact factor: 5.857

9.  Controlled Fab-arm exchange for the generation of stable bispecific IgG1.

Authors:  Aran F Labrijn; Joyce I Meesters; Patrick Priem; Rob N de Jong; Ewald T J van den Bremer; Muriel D van Kampen; Arnout F Gerritsen; Janine Schuurman; Paul W H I Parren
Journal:  Nat Protoc       Date:  2014-09-25       Impact factor: 13.491

10.  Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin (bevacizumab), Remicade (infliximab) and Herceptin (trastuzumab).

Authors:  Bas J M Peters; Martinus A H Capelle; Tudor Arvinte; Ewoudt M W van de Garde
Journal:  MAbs       Date:  2012-12-19       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.